Some Insurers Protected by GINA

Long-term, life, and disability insurers may still be able to deny coverage to patients with a genetic disease, under current nondiscrimination legislation.

Written byEdyta Zielinska
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Artist's rendering of a thinner entorhinal cortex (red), appearing early in people with the ApoE4 gene variantWIKIMEDIA, PHILIP SHAW, NIMHThe Genetic Information Nondiscrimination Act (GINA) of 2008 ensures that employers and health insurers cannot legally discriminate against people with genetic diseases. However, a loophole in the law does allow certain types of insurance, such as long-term insurance, life insurance, and disability insurance, to check patients’ genetic makeup before granting coverage, and can even require patients be tested for genetic diseases.

"GINA was a fabulous accomplishment," Robert Green, a researcher in the genetics department at Harvard Medical School, told NPR. "But I think that it was not perfect," added Green, who investigated how people who are tested for the ApoE4 gene variant, which is associated with a higher risk of Alzheimer’s, react after they discover they carry the variant, and found that many buy long-term-care insurance to help cover nursing home and assisted living facility costs.

Representative Louise Slaughter (D-NY), who originally shepherded GINA through the House, said she is aware of the loopholes and has been working to close them. Insurance companies, on the other hand, say that requiring coverage could cause them to go bankrupt, since their business relies on the income from a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies